Monitor upcoming clinical trial readouts for Haduvio, as the new capital extends the runway but does not change the underlying development risk. Watch for any updates on FDA discussions or trial enrollment progress.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $14.62entry
- T+1 · 7mo ago +1.23%α +0.21% · $14.80
- T+5 · 7mo ago −5.34%α −6.42% · $13.84
- T+20 · 6mo ago −8.14%α −13.05% · $13.43
- T+60 · 4mo ago +18.74%α +11.84% · $17.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, raising approximately $173 million in gross proceeds. The capital raise, which included full exercise of the underwriters' option for 1.74 million additional shares, will support development of its investigational therapy Haduvio for chronic cough conditions.
Key Financial Metrics
Key Facts
- Closed public offering of 13,340,000 shares at $13.00 per share
- Gross proceeds of approximately $173 million before underwriting discounts and expenses
- Underwriters fully exercised option to purchase 1,740,000 additional shares
- Proceeds to fund development of Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC
- Offering conducted under shelf registration (Form S-3) filed November 13, 2025
Financial Impact
$173 million raised, ~35% dilution based on pre-offering market cap of $2.0B and prior share price near $13
Risk Factors
- Significant shareholder dilution from the offering
- Clinical-stage biotech risk: Haduvio has not yet received regulatory approval
- Future financing needs if trial costs exceed expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277454 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Viewing Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers